Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults

Tongji Hospital

Status and phase: Completed; Phase 4

Conditions: Hypotension During Surgery

Treatments: Drug: Remimazolam Tosilate for Injection 0.15mg/kg; Drug: Remimazolam Tosilate for Injection 0.2mg/kg; Drug: Remimazolam Tosilate for Injection 0.1mg/kg

Study type: Interventional

Funder types: Other

Identifiers

NCT04908553

2021S027

Details and patient eligibility

About

Research objective: To explore the safety and dose exploration of Remimazolam Tosilate for Injection for induction and maintenance of general anesthesia in elective short-term surgery in adults.

Main research indicators:(1)Success rate of sedation during induction and maintenance of general anesthesia with remazolam tosylate;(2)The incidence and severity of hypotension in the induction and maintenance phases Study design: Multi-center, randomized, double-blind clinical study. Subject population: patients undergoing elective short-term surgery. Research data collection period: The subject signs the consent form until discharge or death in the hospital or withdrawal from the research.

Number of research centers/sample size: It is planned to enroll 600 patients from 11 hospitals.

Research process: The researchers will include patients who meet the enrollment criteria and agree to participate in the investigation of the support laryngoscope surgery and minor head and neck surgery patients from the elective surgery patients.

Full description

The data collected in this study is recorded by the researcher in the eCRF, including:

1. Data to be collected during the screening period and before the operation: the basic characteristics of the patient and demographic data;
2. Data to be recorded during and/or postoperatively: main research indicators, secondary indicators and other indicators.

Enrollment: 650 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. ASA Ⅰ-Ⅲ grade;
2. age 18-65 years old;
3. gender is not limited;
4. planned elective support laryngoscope surgery (glottic polypectomy under support laryngoscope, epiglottic cyst excision under support laryngoscope, benign laryngeal under support laryngoscope Lesion resection), endoscopic septoplasty, endoscopic tympanoplasty, endoscopic middle ear tube insertion, nasopharyngoplasty, head and neck benign mass resection for general anesthesia intubation patients;
5. operation time No more than 90min.

Exclusion criteria

• Emergency surgery;

1. abnormal renal function (urea nitrogen ≥1.5×ULN, blood creatinine greater than the upper limit of normal);
2. abnormal liver function;
3. hypovolemia, shock or coma;
4. suffering from mental illness and long-term use of psychotropic drugs;
5. cognition Dysfunction;
6. those who are allergic to or contraindicated to benzodiazepines and their drug components; pregnant or lactating female patients;
7. have a history of drug dependence;
8. have used other sedatives in the past week;
9. have been a subject within the past 3 months Participated in drug clinical trials

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

650 participants in 3 patient groups

low dose group

Other group

Description:

Remimazolam Tosilate for Injection 0.1mg/kg at induction

Treatment:

Drug: Remimazolam Tosilate for Injection 0.1mg/kg

medium dose group

Other group

Description:

Remimazolam Tosilate for Injection 0.15mg/kg at induction

Treatment:

Drug: Remimazolam Tosilate for Injection 0.15mg/kg

high dose group

Other group

Description:

Remimazolam Tosilate for Injection 0.2mg/kg at induction

Treatment:

Drug: Remimazolam Tosilate for Injection 0.2mg/kg